Surface Oncology Profit Margin 2017-2018 | SURF
Current and historical gross margin, operating margin and net profit margin for Surface Oncology (SURF) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Surface Oncology net profit margin as of December 31, 2018 is -11.1%.
|Surface Oncology Annual Profit Margins
|Surface Oncology Quarterly Profit Margins
||Medical Products Manufacturing
Surface Oncology, Inc. is a clinical-stage immuno-oncology company. It develops therapies for the treatment of cancer. The company's product pipeline includes CD47, CD73, SRF231, SRF373, SRF617, SRF388 and SRF231 which are in clinical stage. Surface Oncology is based in Cambridge, Massachusetts.